全球生物模擬市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計生物模擬市場將從 2025 年的 47.7 億美元成長到 2034 年的 203.1 億美元，2026 年至 2034 年的複合年成長率為 17.47%。

受計算技術進步、研發投入增加以及製藥、生物技術和學術領域應用日益廣泛推動，全球生物模擬市場持續成長。計算能力的提升和生物模型的日益精細化提高了模擬精度，從而有助於藥物發現和臨床前開發階段的早期決策。隨著企業努力縮短產品上市時間並降低研發成本，生物模擬平台已從利基應用轉變為研發流程的核心組成部分，從而促進了收入成長並擴大了市場滲透率。

全球生物模擬市場的主要促進因素包括縮短研發週期的壓力、監管機構對替代測試方法的鼓勵，以及臨床前研究中成本控制日益重要。機器學習、雲端運算和大規模註釋生物資料集等技術基礎正在加速模型準確性和可及性的提升，並降低中小企業的准入門檻。軟體供應商、受託研究機構(CRO) 和生命科學公司之間的合作，以及公共部門對數位生物學舉措的資助，進一步加速了生物模擬技術的應用。

隨著系統生物學、人工智慧和多尺度建模的融合，全球生物模擬市場前景廣闊，建構了一個更豐富、更可預測的平台，為精準醫療提供支援。檢驗研究、標準化工作和互通性是獲得監管部門核准以及拓展應用場景（從藥物發現到個人化醫療和安全性評估）的關鍵。能夠提供整合化、用戶友善套件並展現臨床和監管價值的供應商，最有希望抓住不斷成長的市場需求，尤其是在新興市場。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球生物模擬市場：依產品分類

• 市場分析、洞察與預測
• 軟體（分子建模、臨床試驗設計、PK/PD建模、PBPK建模、毒性預測等）
• 服務

第5章 全球生物模擬市場：依應用分類

• 市場分析、洞察與預測
• 藥物發現與開發
• 疾病建模
• 其他領域（精準醫療、毒理學等）

第6章 全球生物模擬市場：依治療領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 心血管疾病
• 感染疾病
• 神經系統疾病
• 其他

第7章 全球生物模擬市場：依部署模式分類

• 市場分析、洞察與預測
• 基於雲端的
• 現場
• 混合模式

第8章：全球生物模擬市場：依定價模式

• 市場分析、洞察與預測
• 基於許可的模式
• 訂閱模式
• 基於服務的模式
• 計量收費模式

第9章 全球生物模擬市場：依最終用途分類

• 市場分析、洞察與預測
• 生命科學公司
• 學術研究機構
• 其他（例如，監管機構）

第10章 全球生物模擬市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Certara
  • USA. Dassault SystAfA¨Mes
  • Advanced Chemistry Development
  • Simulation Plus
  • Schrodinger Inc
  • Chemical Computing Group ULC
  • Physiomics Plc. Rosa & Co. LLC
  • BioSimulation Consulting Inc
  • Genedata AG
  • Instem Group Of Companies
  • PPD Inc
  • Yokogawa Insilico Biotechnology GmbH

The Biosimulation Market size is expected to reach USD 20.31 Billion in 2034 from USD 4.77 Billion (2025) growing at a CAGR of 17.47% during 2026-2034.

The Global Biosimulation Market has experienced steady expansion as advancements in computing, growing R&D investment, and broader adoption across pharmaceutical, biotech, and academic sectors converge. Increased computational power and more sophisticated biological models have improved simulation fidelity, enabling earlier decision-making in drug discovery and preclinical development. As companies seek to reduce time-to-market and development costs, biosimulation platforms have moved from niche use to core components of research pipelines, sustaining revenue growth and wider market penetration.

Key drivers for the Global Biosimulation Market include pressure to shorten development cycles, regulatory encouragement for alternative testing methods, and the rising emphasis on cost containment in preclinical research. Technological enablers such as machine learning, cloud computing, and larger annotated biological datasets accelerate model accuracy and accessibility, lowering barriers to entry for smaller organizations. Partnerships between software providers, contract research organizations, and life science firms, along with public funding for digital biology initiatives, further amplify adoption.

Future prospects for the Global Biosimulation Market are promising as systems biology, AI, and multi-scale modeling converge to create richer, more predictive platforms that support precision therapeutics. Validation studies, standardization efforts, and interoperability will be key to regulatory acceptance, broadening use cases from drug discovery to personalized medicine and safety assessment. Vendors that offer integrated, user-friendly suites and demonstrate clinical and regulatory value are best positioned to capture expanding demand, particularly in emerging markets.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Software (Molecular Modeling & Simulation Software, Clinical Trial Design Software, PK/PD Modeling and Simulation Software, bpk Modeling and Simulation Software, Toxicity Prediction Software, Other Software)
• Services

By Application

• Drug Discovery & Development
• Disease Modeling
• Other (Precision Medicine, Toxicology, etc.)

By Therapeutic Area

• Oncology
• Cardiovascular Disease
• Infectious Disease
• Neurological Disorders
• Others

By Deployment Model

• Cloud-based
• On-premise
• Hybrid Model

By Pricing Model

• License-based Model
• Subscription-based Model
• Service-based Model
• Pay Per Use Model

By End Use

• Life Sciences Companies
• Academic Research Institutions
• Others (Regulatory Authorities, etc.)

COMPANIES PROFILED

• Certara, USA Dassault Systmes, Advanced Chemistry Development, Simulation Plus, Schrodinger Inc, Chemical Computing Group ULC, Physiomics Plc Rosa Co LLC, BioSimulation Consulting Inc, Genedata AG, Instem Group of Companies, PPD Inc, Yokogawa Insilico Biotechnology GmbH
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMULATION MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Software (Molecular Modeling & Simulation Software, Clinical Trial Design Software, PK/PD Modeling and Simulation Software, bpk Modeling and Simulation Software, Toxicity Prediction Software, Other Software) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMULATION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Disease Modeling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other (Precision Medicine, Toxicology, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMULATION MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapeutic Area
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOSIMULATION MARKET: BY DEPLOYMENT MODEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Deployment Model
• 7.2. Cloud-based Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. On-premise Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Hybrid Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOSIMULATION MARKET: BY PRICING MODEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Pricing Model
• 8.2. License-based Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Subscription-based Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Service-based Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Pay Per Use Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BIOSIMULATION MARKET: BY END USE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End Use
• 9.2. Life Sciences Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Academic Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Others (Regulatory Authorities, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BIOSIMULATION MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Product
  • 10.2.2 By Application
  • 10.2.3 By Therapeutic Area
  • 10.2.4 By Deployment Model
  • 10.2.5 By Pricing Model
  • 10.2.6 By End Use
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Product
  • 10.3.2 By Application
  • 10.3.3 By Therapeutic Area
  • 10.3.4 By Deployment Model
  • 10.3.5 By Pricing Model
  • 10.3.6 By End Use
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Product
  • 10.4.2 By Application
  • 10.4.3 By Therapeutic Area
  • 10.4.4 By Deployment Model
  • 10.4.5 By Pricing Model
  • 10.4.6 By End Use
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Product
  • 10.5.2 By Application
  • 10.5.3 By Therapeutic Area
  • 10.5.4 By Deployment Model
  • 10.5.5 By Pricing Model
  • 10.5.6 By End Use
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Product
  • 10.6.2 By Application
  • 10.6.3 By Therapeutic Area
  • 10.6.4 By Deployment Model
  • 10.6.5 By Pricing Model
  • 10.6.6 By End Use
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL BIOSIMULATION INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Certara
  • 12.2.2 USA. Dassault SystAfA¨Mes
  • 12.2.3 Advanced Chemistry Development
  • 12.2.4 Simulation Plus
  • 12.2.5 Schrodinger Inc
  • 12.2.6 Chemical Computing Group ULC
  • 12.2.7 Physiomics Plc. Rosa & Co. LLC
  • 12.2.8 BioSimulation Consulting Inc
  • 12.2.9 Genedata AG
  • 12.2.10 Instem Group Of Companies
  • 12.2.11 PPD Inc
  • 12.2.12 Yokogawa Insilico Biotechnology GmbH